The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Heparan Sulfate in Perlecan Promotes Mouse Atherosclerosis: Roles in Lipid Permeability, Lipid Retention, and Smooth Muscle Cell Proliferation
Abstract
Heparan sulfate (HS) has been proposed to be antiatherogenic through inhibition of lipoprotein retention, inflammation, and smooth muscle cell proliferation. Perlecan is the predominant HS proteoglycan in the artery wall. Here, we investigated the role of perlecan HS chains using apoE null (ApoE0) mice that were cross-bred with mice expressing HS-deficient perlecan ( Hspg2 Δ3/Δ3 ). Morphometry of cross-sections from aortic roots and en face preparations of whole aortas revealed a significant decrease in lesion formation in ApoE0/ Hspg2 Δ3/Δ3 mice at both 15 and 33 weeks. In vitro, binding of labeled mouse triglyceride-rich lipoproteins and human LDL to total extracellular matrix, as well as to purified proteoglycans, prepared from ApoE0/ Hspg2 Δ3/Δ3 smooth muscle cells was reduced. In vivo, at 20 minutes influx of human 125 I-LDL or mouse triglyceride-rich lipoproteins into the aortic wall was increased in ApoE0/ Hspg2 Δ3/Δ3 mice compared to ApoE0 mice. However, at 72 hours accumulation of 125 I-LDL was similar in ApoE0/ Hspg2 Δ3/Δ3 and ApoE0 mice. Immunohistochemistry of lesions from ApoE0/ Hspg2 Δ3/Δ3 mice showed decreased staining for apoB and increased smooth muscle α-actin content, whereas accumulation of CD68-positive inflammatory cells was unchanged. We conclude that the perlecan HS chains are proatherogenic in mice, possibly through increased lipoprotein retention, altered vascular permeability, or other mechanisms. The ability of HS to inhibit smooth muscle cell growth may also influence development as well as instability of lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Syndecans (13–16) and perlecan (14, 17, 18) have been shown to mediate the internalization of model remnant lipoproteins or TRL preparations enriched in LPL or apoE.”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic clearance of triglyceride-rich remnants.”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thus, we believe that the genetic data presented here and previously (9), coupled with numerous cell culture studies by other groups over the years (13–19, 21), argue for independent action of proteoglycans in the hepatic”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019
Self-citationSuppression by heparin of smooth muscle cell proliferation in injured arteries
CLOWES, A. W., & KARNOWSKY, M. J. (1977) · Nature · doi:10.1038/265625a0 · Cited by 790
Supramolecular assembly of basement membranes
Timpl, R., & Brown, J. C. (1996) · BioEssays · doi:10.1002/bies.950180208 · Cited by 699
CD40 Signaling and Plaque Instability
Schönbeck, U., & Libby, P. (2001) · Circulation Research · doi:10.1161/hh2401.101272 · Cited by 566
Tangirala, R. K., Rubin, E. M., & Palinski, W. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39713-3 · Cited by 514
The Interaction between Human Plasma Lipoproteins and Connective Tissue Glycosaminoglycans
Iverius, P.-H. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)45469-0 · Cited by 461
Noonan, D. M., Fulle, A., Valente, P., Cai, S., Horigan, E., Sasaki, M., Yamada, Y., & Hassell, J. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54445-8 · Cited by 449
Heparan Sulfate: A Complex Polymer Charged with Biological Activity
Whitelock, J. M., & Iozzo, R. V. (2005) · Chemical Reviews · doi:10.1021/cr010213m · Cited by 410
Iozzo, R. V., Cohen, I. R., Grässel, S., & Murdoch, A. D. (1994) · Biochemical Journal · doi:10.1042/bj3020625 · Cited by 382
Research works printed but not linked: 4
- 10.1161/atvb.22.3.462 · doi:10.1161/atvb.22.3.462
- 10.1002/(SICI)1098-1136(199710)21:2<228::AID-GLIA6>3.0.CO;2-2 · DOI
- 10.1161/atvb.17.10.2150 · doi:10.1161/atvb.17.10.2150
- 10.1161/res.89.12.1092 · doi:10.1161/res.89.12.1092
Cited by
Borén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524
Self-citationStanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226
Gordts, P. L. S. M., Foley, E. M., Lawrence, R., Sinha, R., Lameda-Diaz, C., Deng, L., Nock, R., Glass, C. K., Erbilgin, A., Lusis, A. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.016 · Cited by 86
Manta, C.-P., Leibing, T., Friedrich, M., Nolte, H., Adrian, M., Schledzewski, K., Krzistetzko, J., Kirkamm, C., David Schmid, C., Xi, Y., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058615 · Cited by 84
Metadata
- Authors
- Tran-Lundmark, K., Tran, P.-K., Paulsson-Berne, G., Fridén, V., Soininen, R., Tryggvason, K., Wight, T. N., Kinsella, M. G., Borén, J., & Hedin, U.
- Venue
- Circulation Research
- Published
- 2008-07-03
- Volume
- 103
- Issue
- 1
- Pages
- 43-52
- ISSN
- 0009-7330
- 1524-4571
- Cited by
- 39
- References
- 51
- Language
- en
- Update notices
- correction (2009-01-30)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heparan Sulfate in Perlecan Promotes Mouse Atherosclerosis: Roles in Lipid Permeability, Lipid Retention, and Smooth Muscle Cell Proliferation. https://app.cochat.ai/papers/10.1161/circresaha.107.172833
- The paper
- Tran-Lundmark, K., Tran, P.-K., Paulsson-Berne, G., Fridén, V., Soininen, R., Tryggvason, K., Wight, T. N., Kinsella, M. G., Borén, J., & Hedin, U. (2008). Heparan Sulfate in Perlecan Promotes Mouse Atherosclerosis: Roles in Lipid Permeability, Lipid Retention, and Smooth Muscle Cell Proliferation. Circulation Research. https://doi.org/10.1161/circresaha.107.172833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
